BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 21970875)

  • 1. A combination of serum leucine-rich α-2-glycoprotein 1, CA19-9 and interleukin-6 differentiate biliary tract cancer from benign biliary strictures.
    Sandanayake NS; Sinclair J; Andreola F; Chapman MH; Xue A; Webster GJ; Clarkson A; Gill A; Norton ID; Smith RC; Timms JF; Pereira SP
    Br J Cancer; 2011 Oct; 105(9):1370-8. PubMed ID: 21970875
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mac-2-binding protein is a diagnostic marker for biliary tract carcinoma.
    Koopmann J; Thuluvath PJ; Zahurak ML; Kristiansen TZ; Pandey A; Schulick R; Argani P; Hidalgo M; Iacobelli S; Goggins M; Maitra A
    Cancer; 2004 Oct; 101(7):1609-15. PubMed ID: 15378479
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of a serum biomarker panel for the differential diagnosis of cholangiocarcinoma and primary sclerosing cholangitis.
    Cuenco J; Wehnert N; Blyuss O; Kazarian A; Whitwell HJ; Menon U; Dawnay A; Manns MP; Pereira SP; Timms JF
    Oncotarget; 2018 Apr; 9(25):17430-17442. PubMed ID: 29707118
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Longitudinal analysis of CA19-9 reveals individualised normal range and early changes before development of biliary tract cancer in patients with primary sclerosing cholangitis.
    Wannhoff A; Brune M; Knierim J; Weiss KH; Rupp C; Gotthardt DN
    Aliment Pharmacol Ther; 2019 Mar; 49(6):769-778. PubMed ID: 30687954
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A new strategy for the application of CA19-9 in the differentiation of pancreaticobiliary cancer: analysis using a receiver operating characteristic curve.
    Kim HJ; Kim MH; Myung SJ; Lim BC; Park ET; Yoo KS; Seo DW; Lee SK; Min YI
    Am J Gastroenterol; 1999 Jul; 94(7):1941-6. PubMed ID: 10406263
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Wisteria floribunda agglutinin-sialylated mucin core polypeptide 1 is a sensitive biomarker for biliary tract carcinoma and intrahepatic cholangiocarcinoma: a multicenter study.
    Shoda J; Matsuda A; Shida T; Yamamoto M; Nagino M; Tsuyuguchi T; Yasaka T; Tazuma S; Uchiyama K; Unno M; Ohkohchi N; Nakanuma Y; Kuno A; Narimatsu H
    J Gastroenterol; 2017 Feb; 52(2):218-228. PubMed ID: 27358229
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inflammation But Not Biliary Obstruction Is Associated With Carbohydrate Antigen 19-9 Levels in Patients With Primary Sclerosing Cholangitis.
    Wannhoff A; Rupp C; Friedrich K; Brune M; Knierim J; Flechtenmacher C; Sauer P; Stremmel W; Hov JR; Schirmacher P; Weiss KH; Gotthardt DN
    Clin Gastroenterol Hepatol; 2015 Dec; 13(13):2372-9. PubMed ID: 26192140
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The efficacy of biliary and serum macrophage inhibitory cytokine-1 for diagnosing biliary tract cancer.
    Sugimoto M; Takagi T; Konno N; Suzuki R; Asama H; Watanabe K; Nakamura J; Waragai Y; Kikuchi H; Takasumi M; Sato Y; Hikichi T; Ohira H
    Sci Rep; 2017 Aug; 7(1):9198. PubMed ID: 28835660
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plasma miR-21 is a novel diagnostic biomarker for biliary tract cancer.
    Kishimoto T; Eguchi H; Nagano H; Kobayashi S; Akita H; Hama N; Wada H; Kawamoto K; Tomokuni A; Tomimaru Y; Umeshita K; Doki Y; Mori M
    Cancer Sci; 2013 Dec; 104(12):1626-31. PubMed ID: 24118467
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diagnosis of biliary strictures in conjunction with endoscopic retrograde cholangiopancreaticography, with special reference to patients with primary sclerosing cholangitis.
    Lindberg B; Arnelo U; Bergquist A; Thörne A; Hjerpe A; Granqvist S; Hansson LO; Tribukait B; Persson B; Broomé U
    Endoscopy; 2002 Nov; 34(11):909-16. PubMed ID: 12430077
    [TBL] [Abstract][Full Text] [Related]  

  • 11. FUT2 and FUT3 genotype determines CA19-9 cut-off values for detection of cholangiocarcinoma in patients with primary sclerosing cholangitis.
    Wannhoff A; Hov JR; Folseraas T; Rupp C; Friedrich K; Anmarkrud JA; Weiss KH; Sauer P; Schirmacher P; Boberg KM; Stremmel W; Karlsen TH; Gotthardt DN
    J Hepatol; 2013 Dec; 59(6):1278-84. PubMed ID: 23958938
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development and validation of circulating protein signatures as diagnostic biomarkers for biliary tract cancer.
    Christensen TD; Maag E; Larsen O; Feltoft CL; Nielsen KR; Jensen LH; Leerhøy B; Hansen CP; Chen IM; Nielsen DL; Johansen JS
    JHEP Rep; 2023 Mar; 5(3):100648. PubMed ID: 36699667
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CA19-9 serum levels in obstructive jaundice: clinical value in benign and malignant conditions.
    Marrelli D; Caruso S; Pedrazzani C; Neri A; Fernandes E; Marini M; Pinto E; Roviello F
    Am J Surg; 2009 Sep; 198(3):333-9. PubMed ID: 19375064
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biliary dysplasia in patients with primary sclerosing cholangitis: additional value of DNA ploidity.
    Halme L; Arola J; Numminen K; Krogerus L; Mäkisalo H; Färkkilä M
    Liver Int; 2012 May; 32(5):783-9. PubMed ID: 22098817
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increased level of serum leucine-rich-alpha-2-glycoprotein 1 in patients with clear cell renal cell carcinoma.
    Nakanishi S; Goya M; Suda T; Yonamine T; Sugawa A; Saito S
    BMC Urol; 2024 Apr; 24(1):94. PubMed ID: 38658967
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Blood-based tumor fibrosis markers as diagnostic and prognostic biomarkers in patients with biliary tract cancer.
    Christensen TD; Jensen C; Larsen O; Leerhøy B; Hansen CP; Madsen K; Høgdall D; Karsdal MA; Chen IM; Nielsen D; Johansen JS; Willumsen N
    Int J Cancer; 2023 Mar; 152(5):1036-1049. PubMed ID: 36455598
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CA19-9 antigen levels can distinguish between benign and malignant pancreaticobiliary disease.
    Morris-Stiff G; Teli M; Jardine N; Puntis MC
    Hepatobiliary Pancreat Dis Int; 2009 Dec; 8(6):620-6. PubMed ID: 20007080
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Detection of serum MMP-7 and MMP-9 in cholangiocarcinoma patients: evaluation of diagnostic accuracy.
    Leelawat K; Sakchinabut S; Narong S; Wannaprasert J
    BMC Gastroenterol; 2009 Apr; 9():30. PubMed ID: 19405942
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Elevated tumour marker CA19-9: clinical interpretation and influence of obstructive jaundice.
    Mann DV; Edwards R; Ho S; Lau WY; Glazer G
    Eur J Surg Oncol; 2000 Aug; 26(5):474-9. PubMed ID: 11016469
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical values of CA19-9, CA125 and CEA in malignant obstructive jaundice.
    Ng WW; Tong KJ; Tam TN; Lee SD
    Zhonghua Yi Xue Za Zhi (Taipei); 1995 Jun; 55(6):438-46. PubMed ID: 7634181
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.